Profile data is unavailable for this security.
About the company
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
- Revenue in USD (TTM)0.00
- Net income in USD-67.44m
- Incorporated2016
- Employees163.00
- LocationNautilus Biotechnology Inc2701 Eastlake Ave EastSEATTLE 98102United StatesUSA
- Phone+1 (206) 333-2001
- Fax+1 (302) 655-5049
- Websitehttps://www.nautilus.bio/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 322.66m | 275.00 | -- | 0.5908 | -- | 1.16 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Poseida Therapeutics Inc | 82.50m | -108.86m | 323.84m | 335.00 | -- | 3.82 | -- | 3.93 | -1.18 | -1.18 | 0.8907 | 0.8739 | 0.2864 | -- | 8.06 | 250,006.10 | -37.78 | -40.70 | -49.17 | -47.72 | -- | -- | -131.94 | -233.49 | -- | -12.88 | 0.4096 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -163.66m | 325.10m | 74.00 | -- | 0.6446 | -- | -- | -1.96 | -1.96 | 0.00 | 5.99 | 0.00 | -- | -- | 0.00 | -27.48 | -5.90 | -28.78 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| MacroGenics Inc | 43.36m | -23.24m | 333.84m | 339.00 | -- | 3.14 | -- | 7.70 | -0.3754 | -0.3754 | 0.6969 | 1.70 | 0.1465 | 5.13 | 2.00 | 127,896.80 | -7.85 | -37.76 | -9.48 | -45.53 | 84.28 | -- | -53.60 | -133.96 | 3.61 | -96.21 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| XOMA Royalty Corp | 5.81m | -45.09m | 336.12m | 13.00 | -- | 4.08 | -- | 57.84 | -3.92 | -3.92 | 0.5053 | 7.08 | 0.0329 | -- | 1,291.33 | 447,000.00 | -22.44 | -4.55 | -24.19 | -4.94 | -- | -- | -681.69 | -31.87 | -- | -24.55 | 0.5944 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Prelude Therapeutics Inc | 0.00 | -125.55m | 338.37m | 128.00 | -- | 1.23 | -- | -- | -1.88 | -1.88 | 0.00 | 5.01 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Cabaletta Bio Inc | 0.00 | -76.87m | 342.28m | 118.00 | -- | 1.54 | -- | -- | -1.73 | -1.73 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -44.70 | -33.76 | -48.55 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -166.20m | 346.47m | 74.00 | -- | 2.04 | -- | -- | -3.71 | -3.71 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -67.73 | -34.34 | -76.12 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.067 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -79.79m | 349.33m | 54.00 | -- | 3.13 | -- | -- | -1.70 | -1.70 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -57.38 | -40.29 | -64.24 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Inozyme Pharma Inc | 0.00 | -77.11m | 350.72m | 59.00 | -- | 2.95 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 350.74m | 163.00 | -- | 1.41 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -90.25m | 353.09m | 88.00 | -- | 1.65 | -- | -- | -3.94 | -3.94 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.74 | -49.99 | -40.68 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0075 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Foghorn Therapeutics Inc. | 33.90m | -92.95m | 365.72m | 116.00 | -- | -- | -- | 10.79 | -2.21 | -2.21 | 0.8046 | -2.29 | 0.108 | -- | -- | 292,206.90 | -29.61 | -31.35 | -35.75 | -35.69 | -- | -- | -274.23 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| AC Immune SA | 16.61m | -61.26m | 366.04m | 133.00 | -- | 2.25 | -- | 22.04 | -0.687 | -0.687 | 0.1869 | 1.64 | 0.088 | -- | 61.04 | 124,899.80 | -32.45 | -18.25 | -35.04 | -19.52 | -- | -- | -368.77 | -148.29 | -- | -- | 0.0225 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Vanda Pharmaceuticals Inc. | 177.60m | -4.89m | 366.65m | 203.00 | -- | 0.674 | -- | 2.06 | -0.0846 | -0.0846 | 3.08 | 9.35 | 0.2738 | 10.32 | 5.80 | 874,896.60 | -0.7538 | 6.61 | -0.8808 | 7.62 | 92.42 | 90.55 | -2.75 | 15.18 | 4.69 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| ADC Therapeutics SA | 68.62m | -227.23m | 371.29m | 273.00 | -- | -- | -- | 5.41 | -2.77 | -2.77 | 0.8368 | -2.35 | 0.1769 | 0.2683 | 2.91 | 251,351.60 | -56.99 | -48.41 | -69.99 | -55.63 | 93.30 | -- | -322.09 | -308.62 | 4.35 | -4.14 | 1.85 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
Data as of Jul 24 2024. Currency figures normalised to Nautilus Biotechnology Inc's reporting currency: US Dollar USD
25.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 14 Jun 2024 | 12.59m | 10.05% |
| Cercano Management LLCas of 31 Mar 2024 | 7.17m | 5.73% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.02m | 2.41% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.82m | 2.25% |
| Comprehensive Financial Management LLC (California)as of 31 Mar 2024 | 2.21m | 1.76% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.11m | 0.88% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 938.05k | 0.75% |
| Tikvah Management LLCas of 31 Mar 2024 | 726.90k | 0.58% |
| The Clarius Group LLCas of 30 Jun 2024 | 636.53k | 0.51% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 514.28k | 0.41% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
